Biotech Values

[biocqr]

WVE > Wave Life Sciences on RRS...

https://t.co/RdLeewDjfQ

S-1...
http://www.streetinsider.com/IPOs/WAVE+Life+Sciences+(WVE)+Files+$80M+Common+Stock+IPO/10964214.html

WAVE Life Sciences is a preclinical biopharmaceutical company with an innovative and proprietary synthetic chemistry drug development platform that we are using to design, develop and commercialize a broad pipeline of first-in-class or best-in-class nucleic acid therapeutic candidates. Nucleic acid therapeutics have the potential to address diseases that have been difficult to treat with small molecule drugs or biologics and have emerged as a large and promising class of drugs. We are initially developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Our platform is driven by our innovative and proprietary stereochemistry technology, enabling us to rationally design, optimize and manufacture stereopure nucleic acid therapeutics, which we believe possess drug properties that are superior to the stereoisomer mixtures of oligonucleotides currently on the market or in development by others. Building upon the innovative work of our scientific founders, Gregory L. Verdine, Ph.D. and Takeshi Wada, Ph.D., we have demonstrated the benefits of our stereopure nucleic acid therapeutics in preclinical studies. Our platform can be used to design therapies that utilize any of the major molecular mechanisms employed by nucleic acid therapeutics, including antisense, ribonucleic acid interference, or RNAi, exon skipping and others.